Rurioctocog alfa pegol

N/A

Report date: 2026/04/08 15:32:51

Base Information

Drug NameRurioctocog alfa pegol

Drug Alias Name沃尼凝血素αLA rFVIII PEG (Baxalta)Extended half-life recombinant FVIII (Baxalta)Antihemophilic Factor (Recombinant), PEGylatedPEGylated recombinant factor VIII (Baxalta) +[16]

ClassificationBiologics > Protein drugs > Recombinant protein > Recombinant coagulation factor

Mechanisms of ActionCoagulation factor VIII replacementsCoagulation factor X stimulantsBlood coagulation pathway activation

TargetsCoagulation factor X

Therapy Area/IndicationsHemophilia A

Global Approved IndicationsHemophilia A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryUnited States

Original Approved Date2015/11/13

Country/TerritoryCzechiaBelgiumBulgaria +[35]

CombinationsNo

Global Highest StatusApproved

Highest Status in ChinaNDA/BLA

Originator CompaniesBaxalta Incorporated Nektar Therapeutics

China Registration ClassN/A

Develop Information

Active CompaniesTakeda (China) International Trading Co Ltd Shire Pharmaceuticals Baxalta Innovations Gmbh +[9]

Inactive CompaniesN/A

Active IndicationsHemophilia A

Inactive IndicationsN/A

Other Information

ATC CodeB02BD02